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Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) transactivates EBV genes in latently infected B cells.
We have shown that mitotic hyperphosphorylation of EBNA2 suppresses its ability to transactivate the latent
membrane protein 1 (LMP1) promoter. In this follow-up study, we identify EBNA2 Ser243 as a phosphory-
lation site for mitotic cdc2/cyclin B1 kinase. Mutation at Ser243, which mimics constitutive phosphorylation of
the protein, decreases endogenous levels of both LMP1 and EBNA2. Moreover, mutation at Ser243 reduces the
ability of EBNA2 to transactivate Cp, the promoter for all six EBV EBNA genes. Our data implicate EBNA2
Ser243 as a cdc2/cyclin B1 site of phosphorylation important for EBNA2’s cotranscriptional function in
mitosis.
Epstein-Barr virus (EBV) is associated with the develop-
ment of certain malignancies (5, 15). EBV’s oncogenic poten-
tial is mirrored in vitro, where establishment of latent infection
in human B lymphocytes leads to the outgrowth of immortal-
ized lymphoblastoid cell lines (LCLs) (25, 33). EBV gene ex-
pression in LCLs is restricted to six nuclear antigens (EBNA1,
-2, -3A, -3B, -3C, and -LP), three integral membrane proteins
(LMP1, -2A, and -2B) and two nonpolyadenylated RNAs
(EBER1 and -2) (reviewed in reference 36). EBNA2 is essen-
tial for EBV transformation; EBV with a region of the genome
that contains EBNA2 deleted is unable to transform B lym-
phocytes, and correction of the deletion through genomic re-
combination restores transforming ability (8). EBNA2 trans-
activates all of the other latency gene promoters, including Cp,
from which all six EBNAs are transcribed (17, 40), and the
LMP1 (1, 43) and LMP2A (48, 49) promoters, from which the
three latent membrane proteins (LMPs) are transcribed.
EBV maintains life-long latency in host cells. In latently
infected LCLs or tumor cells EBV is usually maintained as an
episome with copy numbers essentially constant in each cell
line (26, 36), and the latent EBV episomes are located in
chromosomes (37, 38). There have been extensive reports
about transactivation and regulation of EBV latent gene pro-
moters (16, 17, 20, 43); however, most studies were carried out
in asynchronously growing cells, and little is known about tran-
scription from EBV episomes in mitosis when transcription
from host chromosomes is generally suppressed (13, 34, 41).
We recently reported that in type III latency EBNA2 is
hyperphosphorylated specifically in mitosis, which suppresses
transactivation of the LMP1 promoter. We implicated cdc2/
cyclin B1 kinase in this hyperphosphorylation (46). In this
follow-up report, we confirm the importance of hyperphospho-
rylation of EBNA2 in suppressing its function by identifying
Ser243 as a cdc2/cyclin B1 phosphorylation site. Hyperphos-
phorylation at this site impairs not only transcription of the
LMP1 promoter, but also the BamHI C promoter (Cp) used
for transcription of all of the EBNAs.
Ser243 on EBNA2 is a phosphorylation site of cdc2/cyclin B1
kinase. The consensus motif for cdc2 kinase is Ser/Thr-Pro-
X-Z (where X is a polar amino acid and Z is generally a basic
amino acid) (29). In the EBNA2 protein, Ser243 is the most
likely candidate site (sequence SPPR). First, we tested whether
cdc2/cyclin B1 can directly phosphorylate purified EBNA2 at
Ser243 in vitro. Purification of an EBNA2 fragment encoding
185 to 315 amino acids (185-315aa) or 185-315aa S243A, in
which Ser243 was substituted with alanine, and in vitro kinase
assay were described previously (46, 47). As shown in Fig. 1A,
GST-EBNA2 185-315aa fusion protein which contains the po-
tential phosphorylation site Ser243 was phosphorylated by
cdc2/cyclin B1, whereas neither Ser243A substitution in the
GST-EBNA2 185-315aa nor glutathione S-transferase (GST)
was phosphorylated. The results indicate that cdc2/cyclin B1
kinase directly phosphorylates EBNA2 at Ser243 in vitro. Sec-
ond, we studied whether cdc2/cyclin B1 kinase phosphorylates
Ser243 when EBNA2 is expressed in mammalian cells. Wild-
type full-length EBNA2 or EBNA2 with Ser243A substitution
were immunoprecipitated from HeLa cells transiently trans-
fected with either pSG5 EBNA2 (a gift from P. D. Ling) or
pSG5 EBNA2 Ser243A plasmid (47) and subjected to cdc2/
cyclin B1 kinase assay. As shown in Fig. 1B, wild-type EBNA2
can be phosphorylated efficiently in the presence of cdc2/cyclin
B1 kinase, whereas phosphorylation of EBNA2 Ser243A is
greatly diminished. Immunoblot analysis shows that essentially
equal amounts of EBNA2 were used in the kinase assays.
Taken together, the results shown in Fig. 1A and B indicate
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that Ser243 of EBNA2 is a specific phosphorylation site for
cdc2/cyclin B1 kinase.
Ser243 is a mitosis-specific site of EBNA2 phosphorylation.
Since EBNA2 is hyperphosphorylated specifically in mitosis
and cdc2/cyclin B1 is the key regulator of mitosis and has the
highest kinase activity in mitosis, we next ascertained whether
Ser243 is a mitotic-phosphorylation site of EBNA2 in vivo.
Wild-type EBNA2 or EBNA2 Ser243A were transiently ex-
pressed in HeLa cells. At 24 h posttransfection, cells were
synchronized at the G1/S border by double-thymidine blockade
(6). Mitotic cells were collected by vigorous shaking-off 10 h
after release from thymidine block. S-phase and G1-phase cells
(as determined by flow cytometry, data not shown) were col-
lected at 6 and 24 h postrelease, respectively. As exemplified in
Fig. 1C, migration of EBNA2 Ser243A was consistently faster
than that of wild-type EBNA2 in mitotic cells obtained by the
shake-off method. Similar results were also obtained in no-
codazole-arrested mitotic cells (data not shown); however, no
obvious difference in mobility of these two proteins was de-
tected in interphase cells. -Phosphatase assays performed as
described previously (46) confirmed that the shift in migration
of EBNA2 and EBNA2 S243A in mitosis was due to differ-
ences in phosphorylation (data not shown). Therefore, the
results indicate that Ser243 is a mitosis-specific hyperphospho-
rylation site of EBNA2 in vivo.
Phosphorylation at Ser243 suppresses EBNA2 transactiva-
tion function. First, we studied whether phosphorylation of
EBNA2 at Ser243 suppresses its ability to induce expression of
LMP1. P3HR1 is an EBV-positive cell line in which EBNA-LP
and EBNA2 open reading frames are deleted (9), and it ex-
presses only low levels of LMP1; transfected EBNA2 can trans-
activate the endogenous LMP1 promoter and induce LMP1
expression in this cell line (30). Since replacement of serine by
aspartic acid (D) (24, 35) or glutamic acid (E) (22, 23) can
mimic phosphorylation, Ser243 of EBNA2 was mutated to
aspartic acid (D) or glutamic acid (E), and the ability of these
mutated proteins to induce LMP1 expression was compared
when they were exogenously expressed in P3HR1 cells. As
shown in Fig. 2A, wild-type EBNA2 efficiently induces LMP1
protein expression compared to empty vector; however, induc-
tion of LMP1 by the EBNA2 Ser243D or Ser243E mutant
proteins is dramatically suppressed.
RNA protection assays (RPAs) show decreased LMP1
mRNA in EBNA2 Ser243D or Ser243E-transfected P3HR1
cells (Fig. 2B). Therefore, phosphorylation of Ser243 on
EBNA2 can decrease its ability to induce LMP1 RNA consis-
tent with an effect at the transcriptional level. This result is
consistent with and confirms our previous findings that hyper-
phosphorylation of EBNA2 suppresses transactivation of the
LMP1 promoter and produces a decreased steady-state level of
LMP1 mRNA in cells in mitosis (46).
EBNA2 is a nuclear protein (10, 18). We compared the
nuclear localization of wild-type EBNA2 and mutant EBNA2
proteins that are exogenously expressed in p3HR1 cells. As
shown in Fig. 2C, the majority of EBNA2 protein resides in the
nucleus (lane 1), and substitution of Ser243 with D or E (lanes
2 and 3) does not materially affect EBNA2 nuclear localiza-
tion. These results indicate that the inhibitory effect on
EBNA2 function is not due to change in nuclear localization
caused by the substitutions.
To test whether phosphorylation at Ser243 has a general
effect on EBNA2 transactivation function, we chose Cp as a
prototype for study since EBNA2 transactivates Cp, the pro-
moter for all of the EBNAs, as well as the LMP1 promoters.
HeLa cells were chosen for the present study since transacti-
vation of Cp by EBNA2 has been well studied in HeLa cells
(17); more importantly, mitotic cells can be easily separated
from interphase cells by the classical “shake-off” method (19,
42). First, transactivation of Cp by EBNA2 in M phase was
decreased by ca. 50% compared to that in asynchronous cells
(Fig. 3A). To rule out a non-cell-cycle-dependent effect of
nocodazole, we used the irrelevant simian virus 40 early pro-
moter as a control and found that its activity was not affected
FIG. 1. Phosphorylation of cdc2 site Ser243 in vitro and in vivo in
mitosis. (A) Phosphorylation of purified GST-EBNA2 185-313aa
(GST-E2), GST-EBNA2 185-313aa Ser243A (GST-E2 S243A) or GST
in the presence () or absence () of cdc2/cyclin B1 kinase was
carried out. The reaction mixtures were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (4 to 20% gradient gels).
After Coomassie bright blue (CBB) staining, gels were exposed on a
PhosphorImager. (B) Transiently expressed wild-type EBNA2 (wt) or
EBNA2 S243A in HeLa cells were immunoprecipitated by EBNA2
antibody and used as substrates for cdc2/cyclin B1 kinase assays. Im-
munocomplexes were resolved by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis and transferred onto membrane; phosphoryla-
tion of EBNA2 was detected by autoradiography (top panel). Equal
protein levels of EBNA2 were confirmed by immunoblotting (bottom
panel). (C) Migration of wild-type EBNA2 and EBNA2 Ser243 in
different phases of the cell cycle. HeLa cells were synchronized at the
G1/S border by double-thymidine block. S- and G1-phase cells were
collected 6 and 24 h after release from thymidine, and M-phase cells
were collected by vigorous shaking-off at 10 h after release.
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by nocodazole, similar to previous observations (46; data not
shown).
Second, we studied whether phosphorylation at Ser243 is
involved in such suppression. As shown in Fig. 3B, transacti-
vation of Cp by EBNA2 Ser243D is consistently lower than by
wild-type EBNA2 (ca. 50% less), whereas EBNA2 Ser243A
transactivation activity is similar to that of wild-type EBNA2.
EBNA2 Ser243E has an effect similar to that of EBNA2
Ser243D (data not shown). These results suggest that phos-
phorylation at Ser243 is involved in suppression of EBNA2
transactivation of Cp.
Third, the endogenous mRNA levels of EBNA2 in asynchro-
nously growing and mitotically arrested LCL-1 cells were com-
pared. As shown in Fig. 4, in M phase the steady-state level of
EBNA2 mRNA is ca. 56% of that detected in asynchronously
growing cells. Transcription of all of the EBNA genes is driven
by one of two promoters, Cp or Wp, and the activity of these
promoters is mutually exclusive (39, 44, 45). Wp is used during
the initial stages of B-cell immortalization, followed by a switch
to Cp usage (39, 44, 45). In this experiment, transcription of
EBNA2 from Cp but not Wp was confirmed by reverse tran-
scription-PCR (21; data not shown). These and our previous
(46) results indicate that activity of the two major EBV latency
promoters LMP1p and Cp is suppressed in mitosis.
In addition to Ser243, there might be other sites phosphor-
ylated on EBNA2 in mitosis, since migration of EBNA2
Ser243A from mitotic cells is still retarded compared to its
counterpart in asynchronously growing cells (Fig. 1C). Al-
though whether other such sites also participate in suppressing
EBNA2 transactivation function is unknown, our data indicate
that phosphorylation at Ser243 by itself is sufficient to suppress
EBNA2’s ability to induce endogenous LMP1 transcription in
P3HR1 cells (Fig. 2A and B) and transactivate Cp (Fig. 3B),
and therefore Ser243 is a principal site for regulation of
EBNA2 function in mitosis. The results suggest that the sup-
pression of EBNA2 transactivation of viral promoters in mi-
tosis involves cdc2/cyclin B1 phosphorylation at Ser243.
Phosphorylation at Ser243 generally suppresses EBNA2
transactivation function most likely during mitosis, since the
Ser243 site does not seem to be phosphorylated in S and G1
FIG. 2. Induction of endogenous LMP1 expression in P3HR1 cells by EBNA2. Wild-type EBNA2, EBNA2 Ser243D, or EBNA2 Ser243E were
transiently expressed in P3HR1 cells through electroporation. Transfection with empty vector was used as control. (A) Whole-cell lysates were
subjected to immunoblotting for LMP1 and EBNA2 48 h after transfection. -Actin was used as a loading control. (B) Transfected cells were
selected with anti-CD4 magnetic beads, and total RNA was extracted and subjected to RPA for LMP1 and GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) RNAs. Yeast RNA was used as negative and X50-7 RNA positive controls. A histogram quantifying LMP1 mRNA signals by
normalization with GAPDH mRNA signals is shown. (C) Immunoblotting of EBNA2 in P3HR1 cells after nuclear and cytoplasm separation 48 h
posttransfection. Lanes 1, 2, 3, and 4 contained EBNA2 Ser243E, EBNA2 Ser243D, wild-type EBNA2, and vector, respectively. Lamin B is used
as a nuclear marker.
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phase (Fig. 1C). In eukaryotic cells, entry into mitosis is ac-
companied by a global inhibition of transcription (34, 41), and
this transcriptional repression is thought to be required for the
accurate division of chromosomes during mitosis (reviewed in
reference 13). Transcriptional repression in mitosis is regu-
lated at different levels, among which phosphorylation of a
series of transcriptional factors by a mitotic kinase, in most
cases involved with cdc2/cyclin B1 kinase, is one of the impor-
tant mechanisms (13). The behavior of EBV episomes resem-
bles that of host cellular DNA in terms of being packaged in a
nucleosomal structure, replicated once per cell cycle (12, 37),
and partitioned at mitosis (7). We report here another simi-
larity between viral episomal and host gene behavior during
the cell cycle: suppression of viral transcription during mitosis,
likely produced by phosphorylation with cdc2/cyclin B1 kinase.
Although mitotic transcriptional suppression might not be ap-
parent at the viral protein level, since EBV products including
EBNA1, EBNA2, and LMP1 have longer half-lives (3, 4, 11,
14) than the duration of mitosis (ca. 1 h [2]), mitotic suppres-
sion of EBV episomal transcription might nonetheless have a
biological impact similar to mitotic inhibition of cellular tran-
scription machinery (13).
The EBNA2 construct used in the present study is type 1
EBNA2 from the B95-8 strain. Type 2 (AG876) EBNA2 (9), as
well as several EBNA2 homologs from nonhuman primate
lymphocryptoviruses (LCVs), including baboon LCV EBNA2
(28) and rhesus LCV EBNA2 (32), has been identified and
sequenced. Interestingly, as predicted by Scansite (31),
EBNA2 proteins from these other viruses also have putative
cdc2 phosphorylation sites, which implies that EBNA2 ho-
mologs might also be substrates of cdc2 kinase. Although
Ser243 is not conserved among EBNA2 homologs based on
protein alignment (32), all have putative cdc2 phosphorylation
sites within the region adjacent to Ser243 (approximately
amino acids 230 to 250) (Fig. 5), suggesting that this region
might be positionally conserved with regard to phosphorylation
by cdc2 kinase. In fact, a positionally conserved region in
EBNA2 for PKC phosphorylation has been reported (27). It is
FIG. 3. Phosphorylation at Ser243 suppresses EBNA2 transactiva-
tion of the EBV BamHI C promoter, Cp. HeLa cells were cotrans-
fected with reporter plasmid pLuc-Cp and pRL-TK, which encodes the
Renilla luciferase gene in addition to empty vector or EBNA2 expres-
sion vector encoding wild-type EBNA2 (EBNA2 wt) or EBNA2
Ser243D. At 24 h after transfection, cells were arrested in M phase by
nocodazole (M); untreated asynchronously growing cells served as a
control (Asy). Luciferase assays were performed to evaluate promoter
activity. In each phase, transactivation of Cp by EBNA2 is normalized
to the vector control. (A) Decreased transactivation of Cp by EBNA2
in M phase. , P  0.01 versus control. (B) Comparison of transacti-
vation of Cp by wild-type EBNA2, EBNA2 Ser243A and EBNA2
Ser243D. Each datum point (A and B) represents the average of three
independent experiments done in triplicate. Error bars represent the
means  the standard deviation.
FIG. 4. Decreased endogenous steady-state EBNA2 mRNA levels in M-phase-arrested cells. (A) RPA was performed on total RNA from
asynchronously growing (Asy) and M-phase-arrested (M) LCL-1 cells with GAPDH and EBNA2 probe. Yeast RNA or total RNA from DG75 cells
were used as negative controls. A representative result from three independent experiments is shown. (B) Relative mRNA levels of EBNA2 were
analyzed by normalizing EBNA2 mRNA levels to the GAPDH mRNA level with a PhosphorImager. Each datum point represents the average of
three independent experiments. Error bars represent the means  standard deviation (, P  0.01 versus Asy control).
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tempting to predict that similar mitotic transcriptional sup-
pression of EBNA2-responsive genes might occur in type 2
EBV or LCV latently infected cells through cdc2 phosphory-
lation in this conserved region.
Interestingly, Ser243 can also be phosphorylated by the
EBV-encoded cytolytic cycle protein kinase (PK) (47). It is
reasonable to deduce that phosphorylation at Ser243 by EBV
PK might also have a general suppressive effect on EBNA2-
responsive promoters. In LCLs generally transcriptional re-
pression through Ser243 phosphorylation only happens in mi-
tosis, whereas introducing EBV PK into EBV-transformed
LCLs will theoretically repress EBNA2-responsive promoters
constitutively and shut down the expression of latent gene
products with eventual compromise of the type III latency
state. Therefore, Ser243 is not only a key site during the entire
EBV life cycle through which both cellular and viral kinases
modulate EBNA2’s transactivation function but also has po-
tential utilities as a target for gene therapy (E. Gershburg, S.
Kenney, and J. S. Pagano, unpublished data).
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This study was supported in part by a grant from the National
Cancer Institute (CA 19014).
REFERENCES
1. Abbot, S. D., M. Rowe, K. Cadwallader, A. Ricksten, J. Gordon, F. Wang, L.
Rymo, and A. B. Rickinson. 1990. Epstein-Barr virus nuclear antigen 2
induces expression of the virus-encoded latent membrane protein. J. Virol.
64:2126–2134.
2. Alberts, B. B. D., J. Lewis, M. Raff, K. Roberts, and J. D. Watson. 1989. Cell
growth and division, p.729–790. In R. Adams and A. Walker (ed.), Molecular
biology of the cell. Garland Publishing, Inc., New York, N.Y.
3. Aviel, S., G. Winberg, M. Massucci, and A. Ciechanover. 2000. Degradation
of the Epstein-Barr virus latent membrane protein 1 (LMP1) by the ubiq-
uitin-proteasome pathway: targeting via ubiquitination of the N-terminal
residue. J. Biol. Chem. 275:23491–23499.
4. Baichwal, V. R., and B. Sugden. 1987. Posttranslational processing of an
Epstein-Barr virus-encoded membrane protein expressed in cells trans-
formed by Epstein-Barr virus. J. Virol. 63:866–875.
5. Bonnet, M., J. M. Guinebretiere, E. Kremmer, V. Grunewald, E. Benhamou,
G. Contesso, and I. Joab. 1999. Detection of Epstein-Barr virus in invasive
breast cancers. J. Natl. Cancer Inst. 91:1376–1381.
6. Bostock, C. J., D. M. Prescott, and J. B. Kirkpatrick. 1971. An evaluation of
the double thymidine block for synchronizing mammalian cells at the G1-S
border. Exp. Cell Res. 68:163–168.
7. Calos, M. P. 1998. Stability without a centromere. Proc. Natl. Acad. Sci. USA
95:4084–4085.
8. Cohen, J. I., F. Wang, J. Mannick, and E. Kieff. 1989. Epstein-Barr virus
nuclear protein 2 is a key determinant of lymphocyte transformation. Proc.
Natl. Acad. Sci. USA 86:9558–9562.
9. Dambaugh, T., K. Hennessy, L. Chamnankit, and E. Kieff. 1984. U2 region
of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.
Proc. Natl. Acad. Sci. USA 81:7632–7636.
10. Dambaugh, T., F. Wang, K. Hennessy, E. Woodland, A. Rickinson, and E.
Kieff. 1986. Expression of the Epstein-Barr virus nuclear protein 2 in rodent
cells. J. Virol. 59:453–462.
11. Davenport, M. G., and J. S. Pagano. 1999. Expression of EBNA-1 mRNA is
regulated by cell cycle during Epstein-Barr virus type I latency. J. Virol.
73:3154–3161.
12. Dyson, P. J., and P. J. Farrell. 1985. Chromatin structure of Epstein-Barr
virus. J. Gen. Virol. 66:1931–1940.
13. Gottesfeld, J. M., and D. J. Forbes. 1997. Mitotic repression of the tran-
scriptional machinery. Trends Biochem. Sci. 22:197–202.
14. Grasser, F. A., P. Haiss, and N. Mueller-Lantzsch. 1991. Biochemical char-
acterization of Epstein-Barr virus nuclear antigen 2A. J. Virol. 65:3779–3788.
15. Grinstein, S., M. V. Preciado, P. Gattuso, P. A. Chabay, W. H. Warren, E. De
Matteo, and V. E. Gould. 2002. Demonstration of Epstein-Barr virus in
carcinomas of various sites. Cancer Res. 62:4876–4878.
16. Harada, S., and E. Kieff. 1997. Epstein-Barr virus nuclear protein LP stim-
ulates EBNA-2 acidic domain-mediated transcriptional activation. J. Virol.
71:6611–6618.
17. Henkel, T., P. D. Ling, S. D. Hayward, and M. G. Peterson. 1994. Mediation
of Epstein-Barr virus EBNA2 transactivation by recombination signal-bind-
ing protein Jk. Science 265:92–95.
18. Hennessy, K., and E. Kieff. 1983. One of two Epstein-Barr virus nuclear
antigens contains a glycine-alanine copolymer domain. Proc. Natl. Acad. Sci.
USA 80:5665–5669.
19. Jackman, J., and P. M. O’Commor. 1998. Cell cycle analysis, p. 8.0.1–8.0.13.
In J. S. Bonifacino, M. Dasso, J. B. Harford, J. Lippincott-Schwartz, and
K. M. Yamada (ed.), Current protocols in cell biology, vol. 1. John Wiley &
Sons, Inc., New York, N.Y.
20. Johannsen, E., E. Koh, G. Mosialos, X. Tong, E. Kieff, and S. R. Grossman.
1995. Epstein-Barr virus nuclear protein 2 transactivation of the latent mem-
brane protein 1 promoter is mediated by J and PU. 1. J. Virol. 69:253–262.
21. Kelly, G., A. Bell, and A. Rickinson. 2002. Epstein-Barr virus-associated
Burkitt lymphomagenesis selects for downregulation of the nuclear antigen
EBNA2. Nat. Med. 8:1098–1104.
22. Kwiatkowski, B., S. Y. J. Chen, and W. H. Schubach. 2004. CKII site in
Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is
important for growth transformation. J. Virol. 78:6067–6072.
23. Lee, J.-S., K. M. Collins, A. L. Brown, C.-H. Lee, and J. H. Chung. 2000.
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage
response. Nature 404:201–204.
24. Lee, S. Y., M. R. Wenk, Y. Kim, A. C. Nairn, and P. De Camilli. 2004.
Regulation of synaptojanin 1 by cyclin-dependent kinase 5 at synapses. Proc.
Natl. Acad. Sci. USA 101:546–551.
25. Leibold, W., T. D. Flanagan, J. Menezes, and G. Klein. 1975. Induction of
Epstein-Barr virus-associated nuclear antigen during in vitro transformation
of human lymphoid cells. J. Natl. Cancer Inst. 54:65–68.
26. Lindahl, T., A. Adams, G. Bjursell, G. W. Bornkamm, C. Kaschka-Dierich,
and U. Jehn. 1976. Covalently closed circular duplex DNA of Epstein-Barr
virus in a human lymphoid cell line. J. Mol. Biol. 102:511–530.
27. Ling, P. D., and S. D. Hayward. 1995. Contribution of conserved amino acids
in mediating the interaction between EBNA2 and CBF1/RBPJk. J. Virol.
69:1944–1950.
28. Ling, P. D., J. J. Ryon, and S. D. Hayward. 1993. EBNA-2 of herpesvirus
papio diverges significantly from the type A and type B EBNA-2 proteins of
Epstein-Barr virus but retains an efficient transactivation domain with a
conserved hydrophobic motif. J. Virol. 67:2990–3003.
29. Moreno, S., and P. Nurse. 1990. Substrates for p34 cdc2: in vivo veritas? Cell
61:549–551.
30. Ning, S., A. M. Hahn, L. E. Huye, and J. S. Pagano. 2003. Interferon
regulatory factor 7 regulates expression of Epstein-Barr virus latent mem-
brane protein 1: a regulatory circuit. J. Virol. 77:9359–9368.
31. Obenauer, J. C., L. C. Cantley, and M. B. Yaffe. 2003. Scansite 2.0: pro-
teome-wide prediction of cell signaling interactions using short sequence
motifs. Nucleic Acids Res. 31:3635–3641.
32. Peng, R., A. V. Gordadze, E. M. Fuentes Panana, F. Wang, J. Zong, G. S.
Hayward, J. Tan, and P. D. Ling. 2000. Sequence and functional analysis of
EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptovi-
ruses. J. Virol. 74:379–389.
33. Pope, J. H. 1967. Establishment of cell lines from peripheral leucocytes in
infectious mononucleosis. Nature 216:810–811.
34. Prescott, D. M., and M. A. Bender. 1962. Synthesis of RNA and protein
during mitosis in mammalian tissue culture cells. Exp. Cell Res. 26:260–268.
35. Rayet, B., Y. Fan, and C. Gelinas. 2003. Mutations in the v-Rel transactiva-
tion domain indicate altered phosphorylation and identify a subset of NF-
FIG. 5. Alignment of the type 1 (B95-8), type 2 (AG876), baboon
LCV and rhesus LCV EBNA2 amino acid sequences from amino acids
230 to 328. Clusters of amino acids CR5 and CR6 (32) that are
conserved among all four EBNA2 proteins are indicated (boxed), as is
the positionally conserved, cdc2 consensus phosphorylation motif
(boxed). The putative cdc2 phosphorylation sites are marked with an
asterisk.
VOL. 80, 2006 NOTES 2049
B-regulated cell death inhibitors important for v-Rel transforming activity.
Mol. Cell. Biol. 23:1520–1533.
36. Rickinson, A. B., and E. Kieff. 2001. Epstein-Barr virus, p. 2575–2627. In
D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott, Philadel-
phia, Pa.
37. Sexton, C. J., and J. S. Pagano. 1989. Analysis of the Epstein-Barr virus
origin of plasmid replication (oriP) reveals an area of nucleosome sparing
that spans the 3 dyad. J. Virol. 63:5505–5508.
38. Shaw, J. E., L. F. Levinger, and C. W., Jr. Carter. 1979. Nucleosomal
structure of Epstein-Barr virus DNA in transformed cell lines. J. Virol.
29:657–665.
39. Speck, S. H., and J. L. Strominger. 1989. Transcription of Epstein-Barr virus
in latently infected growth-transformed lymphocytes. Adv. Viral. Oncol.
8:133–150.
40. Sung, N. S., S. Kenney, D. Gutsch, and J. S. Pagano. 1991. EBNA-2 trans-
activates a lymphoid-specific enhancer in the Bam H1 C promoter of Ep-
stein-Barr virus. J. Virol. 65:2164–2169.
41. Taylor, J. H. 1960. Nucleic acid synthesis in relation to the cell division cycle.
Ann. N. Y. Acad. Sci. 90:409–421.
42. Terasima, T., and L. J. Tolmach. 1963. Growth and nucleic acid synthesis in
synchronously dividing populations of HeLa cells. Exp. Cell Res. 30:344–362.
43. Wang, F., S. F. Tsang, M. G. Kurilla, J. I. Cohen, and E. Kieff. 1990.
Epstein-Bar virus nuclear antigen 2 transactivates latent membrane protein
LMP-1. J. Virol. 64:3407–3416.
44. Woisetschlaeger, M., J. L. Strominger, and S. H. Speck. 1989. Mutually
exclusive use of viral promoters in Epstein-Barr virus latently infected lym-
phocytes. Proc. Natl. Acad. Sci. USA 86:6498–6502.
45. Woisetschlaeger, M., C. N. Yandava, L. A. Furmanski, J. L. Strominger, and
S. H. Speck. 1990. Promoter switching in Epstein-Barr virus during the initial
stages of infection of B lymphocytes. Proc. Natl. Acad. Sci. USA 87:1725–
1729.
46. Yue, W., M. G. Davenport, J. Shackelford, and J. S. Pagano. 2004. Mitosis-
specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 sup-
presses its function. J. Virol. 78:3542–3552.
47. Yue, W., E. Gershburg, and J. S. Pagano. 2005. Hyperphosphorylation of
EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of
the LMP1 promoter. J. Virol. 79:5880–5885.
48. Zimber-Strobl, U., E. Kremmer, F. Grasser, G. Marschall, G. Laux, and
G. W. Bornkamm. 1993. The Epstein-Barr virus nuclear antigen 2 interacts
with an EBNA-2 responsive cis-element of the terminal protein 1 gene
promoter. EMBO J. 12:167–175.
49. Zimber-Strobl, U., K. O. Suentzenich, G. Laux, D. Eick, M. Cordier, A.
Calender, M. Billaud, G. M. Lenoir, and G. W. Bornkamm. 1991. Epstein-
Barr virus nuclear antigen 2 activates transcription of the terminal protein
gene. J. Virol. 65:415–423.
2050 NOTES J. VIROL.
